EP1402051A4 - Lces als modifikatoren des p53-wegs und verwendungsverfahren - Google Patents
Lces als modifikatoren des p53-wegs und verwendungsverfahrenInfo
- Publication number
- EP1402051A4 EP1402051A4 EP02732039A EP02732039A EP1402051A4 EP 1402051 A4 EP1402051 A4 EP 1402051A4 EP 02732039 A EP02732039 A EP 02732039A EP 02732039 A EP02732039 A EP 02732039A EP 1402051 A4 EP1402051 A4 EP 1402051A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- lces
- modifiers
- pathway
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4739—Cyclin; Prad 1
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29607601P | 2001-06-05 | 2001-06-05 | |
US296076P | 2001-06-05 | ||
US32860501P | 2001-10-10 | 2001-10-10 | |
US328605P | 2001-10-10 | ||
US35725302P | 2002-02-15 | 2002-02-15 | |
US357253P | 2002-02-15 | ||
US36119602P | 2002-03-01 | 2002-03-01 | |
US361196P | 2002-03-01 | ||
PCT/US2002/017739 WO2002099068A2 (en) | 2001-06-05 | 2002-06-03 | Lces as modifiers of the p53 pathway and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1402051A2 EP1402051A2 (de) | 2004-03-31 |
EP1402051A4 true EP1402051A4 (de) | 2005-08-17 |
Family
ID=27501675
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02741809A Withdrawn EP1402262A4 (de) | 2001-06-05 | 2002-06-03 | MAP3Ks ALS MODIFIZIERER DES p53-WEGS UND VERWENDUNGSVERFAHREN |
EP02732039A Withdrawn EP1402051A4 (de) | 2001-06-05 | 2002-06-03 | Lces als modifikatoren des p53-wegs und verwendungsverfahren |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02741809A Withdrawn EP1402262A4 (de) | 2001-06-05 | 2002-06-03 | MAP3Ks ALS MODIFIZIERER DES p53-WEGS UND VERWENDUNGSVERFAHREN |
Country Status (5)
Country | Link |
---|---|
EP (2) | EP1402262A4 (de) |
JP (2) | JP2004532638A (de) |
AU (1) | AU2002314887A1 (de) |
CA (2) | CA2449479A1 (de) |
WO (4) | WO2002098891A2 (de) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10254601A1 (de) * | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
AU2012233044B2 (en) * | 2002-11-22 | 2015-09-03 | Ganymed Pharmaceuticals Ag | Genetic products differentially expressed in tumors and the use thereof |
WO2004058153A2 (en) * | 2002-12-20 | 2004-07-15 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476. |
DE10316701A1 (de) * | 2003-04-09 | 2004-11-04 | Hinzmann, Bernd, Dr. | Humane Nukleinsäuresequenzen aus Bronchialkarzinomen |
EP1657311A4 (de) * | 2003-07-11 | 2006-10-11 | Banyu Pharma Co Ltd | Verfahren zur bewertung einer bei der behandlung von obesität wirksamen verbindung |
EP1677739A4 (de) * | 2003-09-04 | 2008-07-23 | Immusol Inc | Verfahren zur identifizierung von mitteln zur hemmung des wachstums von krebszellen |
WO2005083425A2 (en) * | 2004-02-26 | 2005-09-09 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with mitogen-activated protein kinase kinase kinase 13 (map3k13) |
KR101746412B1 (ko) | 2004-06-04 | 2017-06-14 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | 인쇄가능한 반도체소자들의 제조 및 조립방법과 장치 |
KR101610885B1 (ko) | 2007-01-17 | 2016-04-08 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | 프린팅기반 어셈블리에 의해 제조되는 광학 시스템 |
EP2430652B1 (de) | 2009-05-12 | 2019-11-20 | The Board of Trustees of the University of Illionis | Bedruckte anordnungen aus ultradünnen und mikrofeinen anorganischen leds für verformbare und semitransparente anzeigen |
WO2012097163A1 (en) | 2011-01-14 | 2012-07-19 | The Board Of Trustees Of The University Of Illinois | Optical component array having adjustable curvature |
WO2012158709A1 (en) | 2011-05-16 | 2012-11-22 | The Board Of Trustees Of The University Of Illinois | Thermally managed led arrays assembled by printing |
WO2012167096A2 (en) | 2011-06-03 | 2012-12-06 | The Board Of Trustees Of The University Of Illinois | Conformable actively multiplexed high-density surface electrode array for brain interfacing |
EP2786644B1 (de) | 2011-12-01 | 2019-04-10 | The Board of Trustees of the University of Illionis | Transiente vorrichtungen für programmierbare transformationen |
CN114181944B (zh) * | 2020-09-14 | 2023-10-03 | 中国科学院动物研究所 | 突变基因及构建短肢性侏儒症小型猪模型的方法和用途 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000065054A2 (en) * | 1999-04-23 | 2000-11-02 | Incyte Genomics, Inc. | Human membrane-associated proteins |
WO2001034643A1 (en) * | 1999-11-12 | 2001-05-17 | Human Genome Sciences, Inc. | 24 human secreted proteins |
WO2001075067A2 (en) * | 2000-03-31 | 2001-10-11 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
WO2001098353A2 (en) * | 2000-06-20 | 2001-12-27 | Incyte Genomics, Inc. | Secreted proteins |
WO2002044320A2 (en) * | 2000-11-29 | 2002-06-06 | Xenon Genetics Inc. | Human elongase genes and uses thereof |
WO2002063006A2 (en) * | 2001-02-06 | 2002-08-15 | Incyte Genomics, Inc. | Receptors and membrane-associated proteins |
WO2002062974A2 (en) * | 2001-02-08 | 2002-08-15 | Bayer Aktiengesellschaft | Regulation of human elongase hselo1-like protein |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2104225C (en) * | 1991-02-22 | 2001-07-17 | Leonard Harrison | Method for the diagnosis and treatment of glutamic acid decarboxylase autoantigen associated diseases |
US5405941A (en) * | 1993-04-15 | 1995-04-11 | National Jewish Center For Immunology And Respiratory Medicine | MEKK protein, capable of phosphorylating MEK |
US5554523A (en) * | 1994-03-01 | 1996-09-10 | Children's Hospital Of Philadelphia | Nucleic acid sequences encoding human leucine-zipper protein-kinase |
AU3289599A (en) * | 1998-02-13 | 1999-08-30 | Cadus Pharmaceutical Corporation | Mekk1 proteins and fragments thereof for use in regulating apoptosis |
AU3354499A (en) * | 1998-03-16 | 1999-10-11 | Cadus Pharmaceutical Corporation | Human mekk proteins, corresponding nucleic acid molecules, and uses therefor |
WO2000055330A1 (en) * | 1999-03-18 | 2000-09-21 | The University Of Bristol | Polysaturated fatty acid (pufa) elongase from caenorhabditis elegans |
AU6418000A (en) * | 1999-07-22 | 2001-02-13 | University Of British Columbia, The | A plant long chain fatty acid biosynthetic enzyme |
JP2004506422A (ja) * | 2000-08-11 | 2004-03-04 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 新規マイトジェン活性化キナーゼ |
AU2002250900A1 (en) * | 2001-02-08 | 2002-08-19 | Bayer Aktiengesellschaft | Regulation of human elongase hselo1-like protein |
WO2002096943A1 (en) * | 2001-05-25 | 2002-12-05 | Asahi Kasei Kabushiki Kaisha | Stat6-activating genes |
WO2003091419A2 (en) * | 2002-04-24 | 2003-11-06 | Incyte Corporation | Kinases and phosphatases |
-
2002
- 2002-06-03 WO PCT/US2002/017465 patent/WO2002098891A2/en not_active Application Discontinuation
- 2002-06-03 WO PCT/US2002/017457 patent/WO2002098889A2/en not_active Application Discontinuation
- 2002-06-03 EP EP02741809A patent/EP1402262A4/de not_active Withdrawn
- 2002-06-03 EP EP02732039A patent/EP1402051A4/de not_active Withdrawn
- 2002-06-03 CA CA002449479A patent/CA2449479A1/en not_active Abandoned
- 2002-06-03 CA CA002448112A patent/CA2448112A1/en not_active Abandoned
- 2002-06-03 WO PCT/US2002/017460 patent/WO2002098468A1/en not_active Application Discontinuation
- 2002-06-03 JP JP2003502009A patent/JP2004532638A/ja not_active Withdrawn
- 2002-06-03 WO PCT/US2002/017739 patent/WO2002099068A2/en not_active Application Discontinuation
- 2002-06-03 AU AU2002314887A patent/AU2002314887A1/en not_active Abandoned
- 2002-06-03 JP JP2003502178A patent/JP2005514906A/ja not_active Withdrawn
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000065054A2 (en) * | 1999-04-23 | 2000-11-02 | Incyte Genomics, Inc. | Human membrane-associated proteins |
WO2001034643A1 (en) * | 1999-11-12 | 2001-05-17 | Human Genome Sciences, Inc. | 24 human secreted proteins |
WO2001075067A2 (en) * | 2000-03-31 | 2001-10-11 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
WO2001098353A2 (en) * | 2000-06-20 | 2001-12-27 | Incyte Genomics, Inc. | Secreted proteins |
WO2002044320A2 (en) * | 2000-11-29 | 2002-06-06 | Xenon Genetics Inc. | Human elongase genes and uses thereof |
WO2002063006A2 (en) * | 2001-02-06 | 2002-08-15 | Incyte Genomics, Inc. | Receptors and membrane-associated proteins |
WO2002062974A2 (en) * | 2001-02-08 | 2002-08-15 | Bayer Aktiengesellschaft | Regulation of human elongase hselo1-like protein |
Also Published As
Publication number | Publication date |
---|---|
WO2002098891A3 (en) | 2003-05-30 |
AU2002314887A1 (en) | 2002-12-16 |
EP1402051A2 (de) | 2004-03-31 |
EP1402262A4 (de) | 2005-05-11 |
WO2002098468A1 (en) | 2002-12-12 |
JP2004532638A (ja) | 2004-10-28 |
JP2005514906A (ja) | 2005-05-26 |
CA2448112A1 (en) | 2002-12-12 |
EP1402262A2 (de) | 2004-03-31 |
WO2002098891A2 (en) | 2002-12-12 |
WO2002098889A2 (en) | 2002-12-12 |
CA2449479A1 (en) | 2002-12-12 |
WO2002099068A2 (en) | 2002-12-12 |
WO2002098889A3 (en) | 2003-03-27 |
WO2002099068A3 (en) | 2003-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1401475A4 (de) | Prmts als modifikatoren des p53-pfads und anwendungsverfahren | |
EP1466175A4 (de) | Sphks als modifikatoren des p53-wegs und verwendungsverfahren | |
AU2003213606A8 (en) | Mp53s as modifiers of the p53 pathway and methods of use | |
AU2002364528A8 (en) | Bio-implant and method of making the same | |
AU2002352903A8 (en) | Mesoporous materials and methods | |
EP1402051A4 (de) | Lces als modifikatoren des p53-wegs und verwendungsverfahren | |
EP1434772A4 (de) | Verbindungen und verfahren | |
AU2002239933A1 (en) | Antineoplastic polyalkoxyalkylsiloxanes and methods of use thereof | |
AU2002337916A1 (en) | Modifier of the p53 pathway and methods of use | |
AU2002359694A8 (en) | Compounds and methods | |
EP1418194A4 (de) | Modifiziertes polyalkylenimin und verfahren zu seiner verwendung | |
EP1379240A4 (de) | Verbindungen und verfahren | |
AU2003295881A8 (en) | Lamps as modifiers of the p53 pathway and methods of use | |
AU2003303094A8 (en) | Mat2as as modifiers of the p53 pathway and methods of use | |
AU2002357817A8 (en) | Klcs as modifiers of the p53 pathway and methods of use | |
AU2001268903A1 (en) | Hexaglucal compound and the use and the methods of preparing them | |
AU2002345486A1 (en) | Slc13as as modifiers of the p53 pathway and methods of use | |
AU2002303947A1 (en) | Pecis as modifiers of the p53 pathway and methods of use | |
AU2002303951A1 (en) | Glras as modifiers of the p53 pathway and methods of use | |
AU2002312283A1 (en) | Srpks as modifiers of the p53 pathway and methods of use | |
AU2002314874A1 (en) | Modifiers of the p53 pathway and methods of use | |
AU2002361654A8 (en) | Mbcats as modifiers of the beta-catenin pathway and methods of use | |
AU2002332130A1 (en) | Msrebps as modifiers of the srebp pathway and methods of use | |
EP1435953A4 (de) | Anti-vesicans-verbindungen und verfahren zu ihrer herstellung und verwendung | |
AU2003278811A8 (en) | Ldlrs as modifiers of the p53 pathway and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20031219 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20050624 |
|
17Q | First examination report despatched |
Effective date: 20050923 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20070326 |